164 related articles for article (PubMed ID: 38500886)
21. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
[TBL] [Abstract][Full Text] [Related]
22. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
Emambux S; Tachon G; Junca A; Tougeron D
Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
[TBL] [Abstract][Full Text] [Related]
23. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
24. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in colorectal cancer: rationale, challenges and potential.
Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
[TBL] [Abstract][Full Text] [Related]
26. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
[No Abstract] [Full Text] [Related]
27. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L
Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920
[TBL] [Abstract][Full Text] [Related]
29. Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer.
Jiang Q; Tian C; Wu H; Min L; Chen H; Chen L; Liu F; Sun Y
Chin J Cancer Res; 2022 Aug; 34(4):365-382. PubMed ID: 36199531
[TBL] [Abstract][Full Text] [Related]
30. High endothelial venules proportion in tertiary lymphoid structure is a prognostic marker and correlated with anti-tumor immune microenvironment in colorectal cancer.
Zhan Z; Shi-Jin L; Yi-Ran Z; Zhi-Long L; Xiao-Xu Z; Hui D; Pan YL; Pan JH
Ann Med; 2023 Dec; 55(1):114-126. PubMed ID: 36503344
[TBL] [Abstract][Full Text] [Related]
31. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
[TBL] [Abstract][Full Text] [Related]
32. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
33. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
34. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Quiroga D; Lyerly HK; Morse MA
Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
36. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
[TBL] [Abstract][Full Text] [Related]
37. LDH-A negatively regulates dMMR in colorectal cancer.
Zhang Y; Li J; Wang B; Chen T; Chen Y; Ma W
Cancer Sci; 2021 Aug; 112(8):3050-3063. PubMed ID: 34110068
[TBL] [Abstract][Full Text] [Related]
38. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
40. The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer.
Wang S; Xu B; Zhang Y; Chen G; Zhao P; Gao Q; Yuan L
Cancer Biol Med; 2023 Dec; 21(1):65-82. PubMed ID: 38148328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
